BRD2 and acute myeloid leukemia: A very recent study in AML reported a highly promising PROTAC compound MZ1, which targets and efficiently degrades BRD2, BRD3, and BRD4 proteins in various AML cell lines, and markedly suppress tumor growth in a xenograft mouse model (Ma et al., 2022b).